F Zsigmond

Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease

Péter L. Lakatos, Z Czeglédi, Tamás Szamosi et al. · World Journal of Gastroenterology · 2009 · 113 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +13

Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis

Stephan Miehlke, Daniela E. Aust, Emese Mihály et al. · Gastroenterology · 2018 · 69 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohnʼs disease, while smoking decreases the risk of colectomy in ulcerative colitis

Tamás Szamosi, János Banai, Z Czeglédi et al. · European Journal of Gastroenterology & Hepatology · 2010 · 65 citations

Medicine, Immunology, Surgery +14

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

Anita Bálint, Klaudia Farkas, Károly Palatka et al. · Journal of Crohn s and Colitis · 2015 · 45 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease

Walter Reinisch, I Altorjay, F Zsigmond et al. · Scandinavian Journal of Gastroenterology · 2015 · 31 citations · Full text

Medicine, Hematology, Pharmacotherapy +17